These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 23688814

  • 1. DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy.
    Keyes M, Macaulay C, Hayes M, Korbelik J, Morris WJ, Palcic B.
    Int J Radiat Oncol Biol Phys; 2013 Aug 01; 86(5):829-34. PubMed ID: 23688814
    [Abstract] [Full Text] [Related]

  • 2. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W, Lee J, Chamberlain D, Cunningham J, Yang L, Tay J.
    Int J Radiat Oncol Biol Phys; 2012 Nov 15; 84(4):962-7. PubMed ID: 22494584
    [Abstract] [Full Text] [Related]

  • 3. Primary Gleason grade 4 impact on biochemical recurrence after permanent interstitial brachytherapy in Japanese patients with low- or intermediate-risk prostate cancer.
    Uesugi T, Saika T, Edamura K, Nose H, Kobuke M, Ebara S, Abarzua F, Katayama N, Yanai H, Nasu Y, Kumon H.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):e219-23. PubMed ID: 21640517
    [Abstract] [Full Text] [Related]

  • 4. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG.
    Int J Radiat Oncol Biol Phys; 2008 Jan 01; 70(1):96-101. PubMed ID: 17980505
    [Abstract] [Full Text] [Related]

  • 5. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):600-7. PubMed ID: 21985944
    [Abstract] [Full Text] [Related]

  • 6. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?
    Huang J, Vicini FA, Williams SG, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez AA, Kestin LL.
    Int J Radiat Oncol Biol Phys; 2012 Jul 15; 83(4):1141-8. PubMed ID: 22099043
    [Abstract] [Full Text] [Related]

  • 7. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer.
    Miles EF, Nelson JW, Alkaissi AK, Das S, Clough RW, Broadwater G, Anscher MS, Chino JP, Oleson JR.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):139-46. PubMed ID: 19836161
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B.
    BJU Int; 2004 Dec 01; 94(9):1235-8. PubMed ID: 15610096
    [Abstract] [Full Text] [Related]

  • 9. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2009 Sep 01; 75(1):16-22. PubMed ID: 19289266
    [Abstract] [Full Text] [Related]

  • 10. Patterns of local failure following prostate brachytherapy.
    Stone NN, Stock RG, White I, Unger P.
    J Urol; 2007 May 01; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [Abstract] [Full Text] [Related]

  • 11. High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
    Aluwini S, van Rooij PH, Kirkels WJ, Jansen PP, Praag JO, Bangma CH, Kolkman-Deurloo IK.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):1480-5. PubMed ID: 22285661
    [Abstract] [Full Text] [Related]

  • 12. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V.
    Radiother Oncol; 2012 Aug 01; 104(2):181-6. PubMed ID: 22853851
    [Abstract] [Full Text] [Related]

  • 13. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ, Keyes M, Palma D, Spadinger I, McKenzie MR, Agranovich A, Pickles T, Liu M, Kwan W, Wu J, Berthelet E, Pai H.
    Urology; 2009 Apr 01; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [Abstract] [Full Text] [Related]

  • 14. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, Bottomley D, Ash D.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):50-6. PubMed ID: 20005453
    [Abstract] [Full Text] [Related]

  • 15. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer.
    Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief J, Adamovich E, Wallner KE.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):e225-32. PubMed ID: 21664066
    [Abstract] [Full Text] [Related]

  • 16. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Feb 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 17. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM.
    Int J Radiat Oncol Biol Phys; 2007 Feb 01; 67(2):327-33. PubMed ID: 17084558
    [Abstract] [Full Text] [Related]

  • 18. The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
    Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J.
    Radiother Oncol; 2005 Jun 01; 75(3):303-6. PubMed ID: 15890423
    [Abstract] [Full Text] [Related]

  • 19. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer.
    Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1315-21. PubMed ID: 20044216
    [Abstract] [Full Text] [Related]

  • 20. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy.
    Hawkins CA, Bergstralh EJ, Lieber MM, Zincke H.
    Urology; 1995 Sep 01; 46(3):356-64. PubMed ID: 7544934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.